Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance - Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Viruses Année : 2022

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance

Résumé

Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatment, are susceptible to the emergence of viral resistance and have a high rate of cross-resistance. To counteract these resistant mutants, second-generation INSTI drugs have been developed: Dolutegravir (DTG), Cabotegravir (CAB), and Bictegravir (BIC). However, HIV is also able to develop resistance mechanisms against the second-generation of INSTIs. This review describes the mode of action of INSTIs and then summarizes and evaluates some typical resistance mutations, such as substitution and insertion mutations. The role of unintegrated viral DNA is also discussed as a new pathway involved in conferring resistance to INSTIs. This allows us to have a more detailed understanding of HIV resistance to these inhibitors, which may contribute to the development of new INSTIs in the future.
Fichier principal
Vignette du fichier
viruses-14-02591-v2-1.pdf (2.77 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04253765 , version 1 (27-10-2023)

Identifiants

Citer

Clémence Richetta, Nhat Quang Tu, Olivier Delelis. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance. Viruses, 2022, 14 (12), pp.2591. ⟨10.3390/v14122591⟩. ⟨hal-04253765⟩
42 Consultations
9 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More